SK83199A3 - Novel erythromycin derivatives, method of preparation and application as medicines - Google Patents

Novel erythromycin derivatives, method of preparation and application as medicines Download PDF

Info

Publication number: SK83199A3
Authority: SK; Slovakia
Prior art keywords: formula; compounds; compound; methyl; give
Prior art date: 1996-12-23

Application number

SK831-99A

Other languages

English (en)

Slovak (sk)

Inventor

Constantin Agouridas

Jean-Francois Chantot

Original Assignee

Hoechst Marion Roussel Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-23

Filing date

1997-12-22

Publication date

2000-05-16

1997-12-22 Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc

2000-05-16 Publication of SK83199A3 publication Critical patent/SK83199A3/sk

Links

239000003814 drug Substances 0.000 title claims abstract description 13
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims description 9
238000000034 method Methods 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title claims description 8
229940079593 drug Drugs 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 claims abstract description 59
150000003839 salts Chemical class 0.000 claims abstract description 13
125000003118 aryl group Chemical group 0.000 claims abstract description 11
239000002253 acid Substances 0.000 claims abstract description 10
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 8
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 4
238000003776 cleavage reaction Methods 0.000 claims description 4
125000004122 cyclic group Chemical group 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
230000007017 scission Effects 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
229960003276 erythromycin Drugs 0.000 claims description 3
125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
MWBJRTBANFUBOX-SQYJNGITSA-N (3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclot Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/O)/[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MWBJRTBANFUBOX-SQYJNGITSA-N 0.000 claims description 2
230000000903 blocking effect Effects 0.000 claims description 2
238000010504 bond cleavage reaction Methods 0.000 claims description 2
125000005587 carbonate group Chemical group 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
230000003115 biocidal effect Effects 0.000 abstract description 3
150000007513 acids Chemical class 0.000 abstract description 2
239000000654 additive Substances 0.000 abstract 1
230000000996 additive effect Effects 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
239000000047 product Substances 0.000 description 39
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
239000000203 mixture Substances 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
125000000623 heterocyclic group Chemical group 0.000 description 5
239000000243 solution Substances 0.000 description 5
BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
239000013078 crystal Substances 0.000 description 3
-1 injectables Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 2
AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
QDFXRVAOBHEBGJ-UHFFFAOYSA-N 3-(cyclononen-1-yl)-4,5,6,7,8,9-hexahydro-1h-diazonine Chemical compound C1CCCCCCC=C1C1=NNCCCCCC1 QDFXRVAOBHEBGJ-UHFFFAOYSA-N 0.000 description 2
WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical group C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
201000007100 Pharyngitis Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
241000193985 Streptococcus agalactiae Species 0.000 description 2
241001134658 Streptococcus mitis Species 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
229940047650 haemophilus influenzae Drugs 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000012429 reaction media Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
YHVUVJYEERGYNU-UHFFFAOYSA-N 4',8-Di-Me ether-5,7,8-Trihydroxy-3-(4-hydroxybenzyl)-4-chromanone Natural products COC1(C)CC(O)OC(C)C1O YHVUVJYEERGYNU-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
201000004813 Bronchopneumonia Diseases 0.000 description 1
206010006500 Brucellosis Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
IEMDOFXTVAPVLX-YWQHLDGFSA-N Leucomycin A1 Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 IEMDOFXTVAPVLX-YWQHLDGFSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
206010056430 Staphylococcal sepsis Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000223996 Toxoplasma Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000202898 Ureaplasma Species 0.000 description 1
208000016150 acute pharyngitis Diseases 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
239000012267 brine Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical compound O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000003328 mesylation reaction Methods 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000004540 pour-on Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Molecular Biology (AREA)
Otolaryngology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

SK831-99A 1996-12-23 1997-12-22 Novel erythromycin derivatives, method of preparation and application as medicines SK83199A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9615830A FR2757518B1 (fr)	1996-12-23	1996-12-23	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
PCT/FR1997/002380 WO1998028316A1 (fr)	1996-12-23	1997-12-22	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Publications (1)

Publication Number	Publication Date
SK83199A3 true SK83199A3 (en)	2000-05-16

Family

ID=9498984

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK831-99A SK83199A3 (en)	1996-12-23	1997-12-22	Novel erythromycin derivatives, method of preparation and application as medicines

Country Status (24)

Country	Link
EP (1)	EP0946580B1 (de)
JP (2)	JP4522496B2 (de)
KR (1)	KR20000062286A (de)
CN (1)	CN1246123A (de)
AP (1)	AP9901566A0 (de)
AT (1)	ATE215553T1 (de)
AU (1)	AU726147B2 (de)
BR (1)	BR9713618A (de)
CA (1)	CA2275359A1 (de)
CZ (1)	CZ293732B6 (de)
DE (1)	DE69711689T2 (de)
DK (1)	DK0946580T3 (de)
EA (1)	EA199900589A1 (de)
ES (1)	ES2172827T3 (de)
FR (1)	FR2757518B1 (de)
HU (1)	HUP0001452A3 (de)
ID (1)	ID21883A (de)
IL (1)	IL130510A0 (de)
NO (1)	NO993124L (de)
PL (1)	PL334134A1 (de)
PT (1)	PT946580E (de)
SK (1)	SK83199A3 (de)
TR (1)	TR199901452T2 (de)
WO (1)	WO1998028316A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2757518B1 (fr) *	1996-12-23	1999-06-11	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
YU44900A (sh)	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6720308B1 (en) *	2002-11-07	2004-04-13	Enanta Pharmaceuticals, Inc.	Anhydrolide derivatives having antibacterial activity
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99995A (en) *	1990-11-21	1997-11-20	Roussel Uclaf	Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
JPH0853355A (ja) *	1994-08-12	1996-02-27	Taisho Pharmaceut Co Ltd	Ｉｌ−５産生抑制剤
JP2000501077A (ja) *	1995-11-08	2000-02-02	アボツト・ラボラトリーズ	エリスロマイシンａおよびｂの３−デオキシ−３−デスクラジノース誘導体
DE69723848T2 (de) *	1996-05-07	2004-07-01	Abbott Laboratories, Abbott Park	3-descladinose-2,3-anhydroerythromycin-derivate
FR2757518B1 (fr) *	1996-12-23	1999-06-11	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

1996
- 1996-12-23 FR FR9615830A patent/FR2757518B1/fr not_active Expired - Fee Related
1997
- 1997-12-22 AT AT97952973T patent/ATE215553T1/de not_active IP Right Cessation
- 1997-12-22 KR KR1019997005682A patent/KR20000062286A/ko not_active Withdrawn
- 1997-12-22 DE DE69711689T patent/DE69711689T2/de not_active Expired - Lifetime
- 1997-12-22 ES ES97952973T patent/ES2172827T3/es not_active Expired - Lifetime
- 1997-12-22 PL PL97334134A patent/PL334134A1/xx unknown
- 1997-12-22 CA CA002275359A patent/CA2275359A1/fr not_active Abandoned
- 1997-12-22 TR TR1999/01452T patent/TR199901452T2/xx unknown
- 1997-12-22 AU AU56679/98A patent/AU726147B2/en not_active Ceased
- 1997-12-22 PT PT97952973T patent/PT946580E/pt unknown
- 1997-12-22 DK DK97952973T patent/DK0946580T3/da active
- 1997-12-22 ID IDW990572A patent/ID21883A/id unknown
- 1997-12-22 CN CN97181784A patent/CN1246123A/zh active Pending
- 1997-12-22 AP APAP/P/1999/001566A patent/AP9901566A0/en unknown
- 1997-12-22 HU HU0001452A patent/HUP0001452A3/hu unknown
- 1997-12-22 IL IL13051097A patent/IL130510A0/xx unknown
- 1997-12-22 SK SK831-99A patent/SK83199A3/sk unknown
- 1997-12-22 EA EA199900589A patent/EA199900589A1/ru unknown
- 1997-12-22 EP EP97952973A patent/EP0946580B1/de not_active Expired - Lifetime
- 1997-12-22 JP JP52847498A patent/JP4522496B2/ja not_active Expired - Lifetime
- 1997-12-22 WO PCT/FR1997/002380 patent/WO1998028316A1/fr not_active Ceased
- 1997-12-22 CZ CZ19992279A patent/CZ293732B6/cs not_active IP Right Cessation
- 1997-12-22 BR BR9713618-2A patent/BR9713618A/pt not_active Application Discontinuation
1999
- 1999-06-23 NO NO993124A patent/NO993124L/no not_active Application Discontinuation
2010
- 2010-02-01 JP JP2010020522A patent/JP5188520B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
PL334134A1 (en)	2000-02-14
PT946580E (pt)	2002-09-30
JP5188520B2 (ja)	2013-04-24
JP4522496B2 (ja)	2010-08-11
ATE215553T1 (de)	2002-04-15
KR20000062286A (ko)	2000-10-25
BR9713618A (pt)	2000-04-11
DK0946580T3 (da)	2002-07-22
FR2757518A1 (fr)	1998-06-26
AU5667998A (en)	1998-07-17
CZ293732B6 (cs)	2004-07-14
EP0946580B1 (de)	2002-04-03
DE69711689D1 (de)	2002-05-08
JP2001507011A (ja)	2001-05-29
CA2275359A1 (fr)	1998-07-02
NO993124D0 (no)	1999-06-23
NO993124L (no)	1999-08-20
JP2010132683A (ja)	2010-06-17
ID21883A (id)	1999-08-05
FR2757518B1 (fr)	1999-06-11
HU0001452B (hu)	2000-09-28
ES2172827T3 (es)	2002-10-01
DE69711689T2 (de)	2002-10-17
HUP0001452A3 (en)	2000-10-30
AP9901566A0 (en)	1999-06-30
CZ227999A3 (cs)	1999-10-13
TR199901452T2 (xx)	1999-10-21
EP0946580A1 (de)	1999-10-06
IL130510A0 (en)	2000-06-01
CN1246123A (zh)	2000-03-01
AU726147B2 (en)	2000-11-02
WO1998028316A1 (fr)	1998-07-02
EA199900589A1 (ru)	2000-02-28

Publication	Publication Date	Title
US5527780A (en)	1996-06-18	Erythromycin derivatives
JP4102440B2 (ja)	2008-06-18	新規なエリスロマイシン誘導体、それらの調製方法及びそれらの医薬品としての使用
US5543400A (en)	1996-08-06	Erythromycin compounds
US6664398B2 (en)	2003-12-16	Derivatives of erythromycin, their preparation process and their use as medicaments
US6313101B1 (en)	2001-11-06	Derivatives of erythromycin, their preparation process and their use as medicaments
US6433151B1 (en)	2002-08-13	Erythromycin derivatives, a process for their preparation and their use as medicaments
JP5188520B2 (ja)	2013-04-24	新規なエリスロマイシン誘導体、製造方法及び医薬としての利用
AU721732B2 (en)	2000-07-13	New derivatives of erythromycin, their preparation process and their use as medicaments
KR20000068014A (ko)	2000-11-25	신규 에리트로마이신 유도체, 그의 제조방법 및 의약으로서의용도
AU761551B2 (en)	2003-06-05	Novel 6-deoxy erythromycin derivatives, method for preparing same and use as medicines
MXPA99005840A (en)	2000-04-24	Novel erythromycin derivatives, method of preparation and application as medicines
MXPA99005226A (en)	2000-01-01	Novel erythromycin derivatives, method for preparing them and their use as medicine